Abstract:Background: Non-motor symptoms (NMS) are compulsory clinical features for the clinical diagnosis of multiple system atrophy (MSA), some of which precede motor symptoms onset. To date, few studies have systematically investigated NMS in MSA and the timing of presenting NMS as the disease progresses. Clinically, MSA is difficult to be differentiated from Parkinson's disease (PD) and progressive supranuclear palsy (PSP), and the differences in NMS between MSA and PD/PSP remain unclear. The aim of this study was to compare the burden of NMS between MSA and PD/PSP and to delineate the timing of NMS presentation relative to the onset of motor symptoms in MSA. Methods: A total of 61, 87, and 30 patients with MSA, PD, and PSP, respectively, were enrolled in this study. NMS was systematically assessed in all patients using the NMS scale (NMSS), and the onset of NMS relative to the onset of motor symptoms in MSA was investigated. Results: MSA group had higher total NMSS scores (82.15 ± 46.10) than the PD (36.14 ± 30.78) and PSP (50.30 ± 55.05) groups ( p < 0.001 overall). The number distribution pattern of the NMS was significantly different among the three parkinsonian disorders ( p < 0.001 overall). In total, 85.2% of patients with MSA had more than 10 NMS, which was significantly higher than PD (28.7%) and PSP (33.3%). The frequency and scores of many NMSS subdomains and symptoms were higher in MSA than in PD and PSP (all p < 0.05). Multivariate logistic regression analysis revealed that patients with fainting, lack of motivation, swallowing, and loss of sexual interest could be attributed to MSA rather than PD or PSP, while patients with loss of concentration and forgetfulness were characteristic features of PD or PSP rather than MSA. REM-sleep behavior disorder (RBD), constipation, problems having sex, and loss of sexual interest preceded the motor symptoms onset of MSA by 2.81 ± 4.51, 1.54 ± 6.32, 1.35 ± 4.70, and 0.45 ± 3.61 years, respectively. Conclusion: The NMS spectrum in MSA differs from that of PD and PSP. Patients with MSA have a higher NMS burden than patients with PD or PSP. RBD, constipation, problems having sex, and loss of sexual interest may become early diagnostic clinical markers of MSA.

Data-Driven Subtypes of Multiple System Atrophy and Their Implications for Prognosis

Identifying New Subtypes of Multiple System Atrophy Using Cluster Analysis

Predicting the Prognosis of Multiple System Atrophy Using Cluster and Principal Component Analysis.

Data-driven subtype classification of patients with early-stage multiple system atrophy

Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy

In Vivo Cerebral Metabolic and Dopaminergic Characteristics in Multiple System Atrophy with Orthostatic Hypotension.

Development and Validation of a Prognostic Model to Predict Overall Survival in Multiple System Atrophy

Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity

Non-motor Symptoms and the Quality of Life in Multiple System Atrophy with Different Subtypes.

Sleep disturbances in probable multiple system atrophy

A study on the characteristics of cognitive function in patients with multiple system atrophy in China

Clinical and Pathological Characteristics of Multiple System Atrophy

Surface-Based Neuroimaging Pattern of Multiple System Atrophy

Comparison of the second consensus statement with the movement disorder society criteria for multiple system atrophy: A single-center analysis

The genetic basis of multiple system atrophy

Imaging Markers of Multiple System Atrophy and Their Association With Disease Severity: A Cross-Sectional Study

Longitudinal Evolution of Motor and Non-Motor Symptoms in Early-Stage Multiple System Atrophy: a 2-Year Prospective Cohort Study

Cerebellar Atrophy and Its Contribution to Motor and Cognitive Performance in Multiple System Atrophy

Clinical and polysomnographic features of patients with multiple system atrophy in Southwest China

Survival analysis and prognostic nomogram model for multiple system atrophy.

The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis